

QUANTUM HEALTHCARE LIMITED
(Company Registration No. 202218645W)
(Incorporated in Singapore)

**TRANSFER OF SHARES IN ASIA DENTAL GROUP PTE. LTD. AND KAIROGENIX PTE. LTD.
PURSUANT TO INTERNAL RESTRUCTURING**

1. INTRODUCTION

The Board of Directors ("**Board**") of Quantum Healthcare Limited ("**Company**", and together with its subsidiaries, "**Group**") refers to the announcements of QT Vascular Ltd. ("**QTV**") on 28 July 2022 in relation to the Scheme and the Scheme Document dated 1 June 2022.

As announced on 28 July 2022, the Scheme has since been completed, and shares of the Company have traded on SGX-ST in lieu of shares in QTV (now a wholly-owned subsidiary of the Company) from 29 July 2022.

Unless otherwise defined, all capitalised terms used herein shall have the same meanings ascribed in the Scheme Document.

2. TRANSFER OF SHARES IN ASIA DENTAL GROUP PTE. LTD. AND KAIROGENIX PTE. LTD.

Following completion of the Scheme, the Company has today entered into a share purchase agreement with QTV ("**SPA**"), effecting the transfer of 60% shares in Asia Dental Group Pte. Ltd. ("**ADG**") held by QTV to the Company for a consideration of S\$7.65 million. The consideration is arrived at after taking into consideration the recent purchase price of ADG by QTV as announced by QTV on 25 May 2021. The balance 40% is held by Dr Jimmy Gian, the Group's Chief Operating Officer (Dental).

The SPA also effects the transfer of 70% interest in Kairogenix Pte. Ltd. ("**Kairogenix**") held by QTV to the Company for a consideration of S\$70. The consideration is arrived at after taking into consideration the amount paid by QTV for Kairogenix's paid-up capital. The balance 30% is held by Associate Professor Eric Yap. Please refer to QTV's announcement dated 9 May 2022 for more details on the incorporation of Kairogenix.

The transfer of ADG from QTV to the Company is as per intended in the Scheme Document, whereby the Proposed Transfer of ADG would follow the Proposed Restructuring and the Transfer of Listing Status, resulting in ADG becoming a directly-held subsidiary of the Company and continue carrying out its Healthcare Business.

The transfer of Kairogenix from QTV to the Company aims to streamline the Group's corporate structure.

The Company does not expect the above restructuring to have any material financial impact on the consolidated net tangible assets per share and consolidated earnings per share of the Company and the Group for the current financial year ending 31 December 2022.

None of the directors, substantial shareholders and controlling shareholders of the Company has any interest, direct or indirect, in the above restructuring, save for their interests arising by way of their shareholdings and/or directorships, as the case may be, in the Company.

3. CORPORATE STRUCTURE

For completeness, the corporate structure of the Group as at the date hereof is set out in the Annex (as attached).

BY ORDER OF THE BOARD

Thomas Tan Gim Chua
Chief Executive Officer and Executive Director
8 September 2022

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

CORPORATE STRUCTURE AFTER THE TRANSFER OF SHARES

